• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童急性髓细胞白血病的细胞遗传学:英国医学研究理事会治疗试验 AML 10 和 12。

Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

机构信息

Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Queen Victoria Road, Newcastle-upon-Tyne, UK.

出版信息

J Clin Oncol. 2010 Jun 1;28(16):2674-81. doi: 10.1200/JCO.2009.24.8997. Epub 2010 May 3.

DOI:10.1200/JCO.2009.24.8997
PMID:20439644
Abstract

PURPOSE

Karyotype is an independent indicator of prognosis in acute myeloid leukemia (AML) that is widely applied to risk-adapted therapy. Because AML is rare in children, the true prognostic significance of individual chromosomal abnormalities in this age group remains unclear.

PATIENTS AND METHODS

This cytogenetic study of 729 childhood patients classified them into 22 subgroups and evaluated their incidence and risk.

RESULTS

Rearrangements of 11q23 were the most frequent abnormality found in approximately 16% of patients, with 50% of these in infants. The outcome for all patients with 11q23 abnormalities was intermediate; no difference was observed for those with t(9;11)(p21-22;q23). The core binding factor leukemias with the translocations t(8;21)(q22;q22) and inv(16)(p13q22) occurred at incidences of 14% and 7%, respectively, predominantly in older children, and their prognosis was favorable. An adverse outcome was observed in patients with monosomy 7, abnormalities of 5q, and t(6;9)(p23;q34). Abnormalities of 3q and complex karyotypes, in the absence of favorable-risk features, have been associated with an adverse outcome in adults, but the results were not significant in this childhood series. However, the presence of 12p abnormalities predicted a poor outcome.

CONCLUSION

Because the spectrum of chromosomal changes and their risk association seem to differ between children and adults with AML, biologic differences are emerging, which will contribute to the redefinition of risk stratification for different age groups in the future.

摘要

目的

核型是急性髓细胞白血病(AML)的独立预后指标,广泛应用于风险适应性治疗。由于儿童 AML 较为罕见,因此个体染色体异常在该年龄组中的真正预后意义尚不清楚。

患者和方法

本研究对 729 例儿童患者进行了细胞遗传学研究,将他们分为 22 个亚组,并评估了其发生率和风险。

结果

11q23 重排是最常见的异常,约占患者的 16%,其中 50%发生在婴儿中。所有 11q23 异常患者的结局均为中等;t(9;11)(p21-22;q23)患者之间无差异。具有 t(8;21)(q22;q22)和 inv(16)(p13q22)易位的核心结合因子白血病发生率分别为 14%和 7%,主要发生在大龄儿童中,其预后良好。单体 7、5q 异常和 t(6;9)(p23;q34)患者的预后不良。3q 异常和复杂核型,在没有有利风险特征的情况下,与成人不良预后相关,但在本儿童系列中结果不显著。然而,12p 异常的存在预示着不良预后。

结论

由于 AML 患儿与成人的染色体变化谱及其风险关联似乎不同,因此出现了生物学差异,这将有助于未来为不同年龄组重新定义风险分层。

相似文献

1
Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.儿童急性髓细胞白血病的细胞遗传学:英国医学研究理事会治疗试验 AML 10 和 12。
J Clin Oncol. 2010 Jun 1;28(16):2674-81. doi: 10.1200/JCO.2009.24.8997. Epub 2010 May 3.
2
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.在英国医学研究理事会试验中治疗的 5876 例年轻成年患者中,对罕见重现染色体异常进行细胞遗传学分类的细化:确定其预后意义。
Blood. 2010 Jul 22;116(3):354-65. doi: 10.1182/blood-2009-11-254441. Epub 2010 Apr 12.
3
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.根据 AML-BFM 98 方案,对大量接受统一治疗的儿童急性髓系白血病患者中特定染色体异常的预后影响。
J Clin Oncol. 2010 Jun 1;28(16):2682-9. doi: 10.1200/JCO.2009.25.6321. Epub 2010 May 3.
4
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.急性髓系白血病中 WHO 类型 inv(3)(q21q26.2)/t(3;3)(q21;q26.2) 和其他各种 3q 异常的临床、分子和预后意义。
J Clin Oncol. 2010 Aug 20;28(24):3890-8. doi: 10.1200/JCO.2010.29.2771. Epub 2010 Jul 26.
5
Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome.儿童和青少年急性髓系白血病的细胞遗传学异常和单倍体核型:与临床特征及预后的相关性
Cancer Genet. 2013 Mar;206(3):63-72. doi: 10.1016/j.cancergen.2013.01.001. Epub 2013 Feb 12.
6
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.EVI1 高表达可预测年轻成人急性髓系白血病患者的预后,并与独特的细胞遗传学异常相关。
J Clin Oncol. 2010 Apr 20;28(12):2101-7. doi: 10.1200/JCO.2009.26.0646. Epub 2010 Mar 22.
7
Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.从儿童到成人年龄组急性髓系白血病细胞遗传学和分子遗传学的变化。
Cancer. 2016 Dec 15;122(24):3821-3830. doi: 10.1002/cncr.30220. Epub 2016 Aug 16.
8
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.诊断细胞遗传学对急性髓系白血病预后的重要性:对参加医学研究委员会AML 10试验的1612例患者的分析。医学研究委员会成人及儿童白血病工作组。
Blood. 1998 Oct 1;92(7):2322-33.
9
Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.细胞遗传学异常对首次完全缓解的急性髓系白血病患者异基因骨髓移植后预后的影响。
Biol Blood Marrow Transplant. 2002;8(8):435-43. doi: 10.1053/bbmt.2002.v8.pm12234169.
10
[Clinical and experimental studies of childhood acute myeloid leukemia with 11q23/MLL rearrangements].儿童急性髓系白血病伴11q23/MLL重排的临床与实验研究
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2012 Dec;29(6):677-82. doi: 10.3760/cma.j.issn.1003-9406.2012.06.011.

引用本文的文献

1
The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia.小儿急性髓系白血病造血干细胞移植的特点
Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02685-5.
2
Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group.伴KMT2A(MLL)重排的急性髓系白血病的预后:TROPHY组的多中心研究
Blood Cancer J. 2025 May 2;15(1):84. doi: 10.1038/s41408-025-01293-x.
3
Biological characteristics and prognosis of acute myeloid leukemia in elderly patients.老年急性髓系白血病的生物学特征与预后
Front Genet. 2025 Apr 4;16:1524177. doi: 10.3389/fgene.2025.1524177. eCollection 2025.
4
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.儿童急性白血病中的 Menin 抑制剂:全面综述及建议,旨在与成人白血病和国际社会合作加速进展。
Leukemia. 2024 Oct;38(10):2073-2084. doi: 10.1038/s41375-024-02368-7. Epub 2024 Aug 23.
5
Classic and molecular cytogenetic findings in leukemia patients from the Western part of Romania.罗马尼亚西部地区白血病患者的经典和分子细胞遗传学发现。
Rom J Morphol Embryol. 2024 Apr-Jun;65(2):203-208. doi: 10.47162/RJME.65.2.06.
6
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.优化 KMT2A 重排型小儿急性髓系白血病的细胞遗传学危险度分组。
Blood Adv. 2024 Jun 25;8(12):3200-3213. doi: 10.1182/bloodadvances.2023011771.
7
Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.细胞遗传学异常可预测儿科急性髓系白血病异基因造血干细胞移植后的生存:PDWP/EBMT 研究。
Bone Marrow Transplant. 2024 Apr;59(4):451-458. doi: 10.1038/s41409-024-02197-3. Epub 2024 Jan 15.
8
A new genomic framework to categorize pediatric acute myeloid leukemia.一种新的基因组框架,用于分类儿科急性髓细胞白血病。
Nat Genet. 2024 Feb;56(2):281-293. doi: 10.1038/s41588-023-01640-3. Epub 2024 Jan 11.
9
Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.治疗靶向治疗伴有异常 HOX/MEIS1 表达的小儿急性髓系白血病。
Eur J Med Genet. 2023 Dec;66(12):104869. doi: 10.1016/j.ejmg.2023.104869. Epub 2023 Oct 29.
10
Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies. Venetoclax 联合疗法在儿科血液系统恶性肿瘤中的最新进展。
Int J Mol Sci. 2023 Nov 24;24(23):16708. doi: 10.3390/ijms242316708.